Moderna logo
Moderna Financial Model

Biotech/Pharma Startup Financials (Free Excel Download)

mRNA-based drug platform company using messenger RNA as programmable "software" to instruct cells to produce therapeutic proteins.

Free, no credit card required
Edit in Excel
Created by ex-finance
professionals from Deloitte
Loading...

Used by professionals from

About this model

Moderna’s mRNA platform treats messenger RNA as programmable therapeutic software: the coding region changes by drug while common formulation elements can be reused within a modality. This supports rapid development, cell-free manufacturing, and difficult targets across vaccines, oncology, and localised therapies.

Precommercial revenue came from pharma partnership upfronts and technical milestones, reimbursed R&D and clinical milestones, and government grants. Partners included Merck, AstraZeneca, the Gates Foundation, Alexion, and Vertex. The deck does not disclose royalties or consumer product sales, so the model should focus on pipeline and collaboration economics.

By May 2017, Moderna had 12 nominated development candidates and five Phase I trials. Cumulative partnership upfronts and milestones reached $740 million, total cash sources $1.946 billion, and Q1 2017 cash $1.22 billion. The model should forecast programmes, R&D burn, milestones, grants, manufacturing capex, and cash runway.

A turnkey financial model

Live formulas, no hardcoded values

Outputs are driven by live formulas, so the workbook updates from its assumptions instead of relying on hardcoded results.

All assumptions in one tab

Inputs are clearly marked in the Assumptions tab and separated from calculations, making it clear what to change and what to leave intact.

Statements always balancing

For integrated-statement models, the balance sheet, cash flow, and supporting schedules tie through properly.

Distinct schedules for clarity

Debt, working capital, taxes, and cash flow can get messy quickly. We group calculations in clear schedules, not across disconnected tabs.

No hidden macros or external links

There are no unexplained external workbook links or macros to undermine auditability or portability.

Changes flow through the model

Update a key driver and see the impact carry through the forecast, financing, and return outputs. We never use hardcoded numbers in formulas.

About Moderna

modernatx.com
Read the pitch deck
Moderna pitch deck cover
View on makeslides.com
Total raised
$500.0M
Funding round
Series G
Founded
2017
Category
Biotech/Pharma
Customer
B2B2C
Geography
US-headquartered

How to build a detailed financial model for Moderna

A complete walkthrough of the business, drivers, and assumptions behind the downloadable Moderna model - distilled from its pitch deck and publicly available information.

Product & value proposition

  • Core technology: mRNA is treated as programmable "software of life" - only the coding region (ORF) changes per drug; formulation, 5' and 3' regions are identical across programs within a modality.
  • Key advantages over small molecules and biologics: (1) product abundance - hundreds of previously undruggable intracellular and membrane-bound targets; (2) speed - idea to DC nomination in 7–12 months; (3) lower COGS potential - cell-free manufacturing, single manufacturing infrastructure serves entire pipeline.
  • Platform generates "modalities" (therapeutic toolkits): Prophylactic Vaccines, Therapeutic Vaccines, Intratumoral I/O, Localized Therapeutics - plus research-stage modalities (Secreted, Liver Intracellular, Lung).
  • Research engine: >1,000 novel mRNA deliveries per month; supports parallel multi-arm partner trials.

Market

  • Total pharma/biotech global revenues (2017E): ~$1 trillion for small molecules + biologics combined.
  • Small molecules: $165bn (1994) → $425bn (2004) → $600bn (2014).
  • Biologics: $10bn (1994) → $55bn (2004) → $180bn (2014).
  • Source: Evaluate Ltd., 01-Nov-2016.
  • No SAM or SOM figures provided; no mRNA-specific market sizing given.
  • Addressable indication breadth illustrated via bubble chart (bubble = market opportunity): prophylactic vaccines (low biology risk), therapeutic/personalized vaccines, intratumoral oncology, localized cardio, secreted therapeutics, liver intracellular, and longer-term CNS/ophthalmology - no dollar figures per segment.
  • CMV annual US cost: $2bn (Cannon et al., BMC, 2005).

Revenue model

Three revenue streams - all B2B / institutional; no consumer product sales:

  1. Partnership upfronts & technical milestones - large pharma/biotech pays Moderna upfront + milestones for access to modalities/programs. Partners as of May 2017: Merck ($65mm prophylactic vx + $200mm therapeutic vx), AstraZeneca ($370mm intratumoral I/O + localized), Bill & Melinda Gates Foundation ($100mm potential, secreted), Alexion ($100mm, liver intracellular), Vertex ($20mm, lung).
  2. Reimbursement & product milestones - R&D cost reimbursement and clinical/regulatory milestone payments from partners.
  3. Government grants - DARPA, BARDA (non-dilutive).

No royalty or commercial revenue stream disclosed; deck is pre-commercialization.

Traction & metrics

Pipeline breadth:

  • 12 development candidates (DCs) nominated; 5 in clinical trials (Phase I) as of May 2017; 2 additional INDs opened by FDA; 5 DCs in pre-clinical.
  • DC count at year-end: 0 (2012) → 1 (2014) → 7 (2015) → 12 (today).
  • Drugs in clinical trials: 0 (2012–2014) → 1 (2015) → 5 (today).

Financing sources (cumulative through 2016): | Line | Founding–2012 | 2013 | 2014 | 2015 | 2016 | Total | | -- | -- | -- | -- | -- | -- | -- | | Partnership upfronts & tech milestones | - | $240mm | $100mm | $110mm | $290mm | $740mm | | Reimbursement & product milestones | - | $2mm | $6mm | $12mm | $36mm | $56mm | | Equity issuance | $39mm | $110mm | $471mm | $56mm | $474mm | $1,150mm | | Total sources of cash | $39mm | $352mm | $577mm | $178mm | $800mm | $1,946mm | | Potential total grant | - | $22mm | - | - | $225mm | $247mm | | Grand total potential | $39mm | $374mm | $577mm | $178mm | $1,025mm | $2,193mm | | Year-end cash | $22mm | $330mm | $796mm | $802mm | $1,307mm | - |

Cash position: $1.22bn at end of Q1 2017; >$200mm of grants available.

Cash burn / outflows: | Line | Founding–2012 | 2013 | 2014 | 2015 | 2016E | 2017E Budget | | -- | -- | -- | -- | -- | -- | -- | | R&D | $(8mm) | $(24mm) | $(61mm) | $(124mm) | $(225mm) | - | | G&A | $(7mm) | $(13mm) | $(18mm) | $(20mm) | $(32mm) | - | | CapEx | $(2mm) | $(4mm) | $(17mm) | $(28mm) | $(39mm) | - | | Gross outflows (OpEx + CapEx) | $(17mm) | $(41mm) | $(96mm) | $(172mm) | $(296mm) | >($300mm) | | Year-end cash | $22mm | $330mm | $796mm | $802mm | $1,307mm | ~$1,000mm |

Team: 500 employees, including 300+ scientists and engineers on platform R&D. Platform investment: $100mm annual investment in mRNA platform.

Clinical data (H10N8 flu vaccine, mRNA-1440): 100% seroprotection (HAI ≥1:40) in 23/23 subjects at 100µg dose; 87% MN seroprotection; 0% in placebo.

Competition / moat

  • Moat framing: platform de-risking (if mRNA works once, it works many times); proprietary integrated platform (chemistry, bioinformatics, mRNA engineering, formulation, process, raw materials).
  • vs. small molecules: conventional drug discovery increasingly risky (low-hanging targets gone; N=1 per molecule).
  • vs. recombinant biologics: mRNA can reach intracellular and membrane-bound proteins that biologics cannot.
  • No named competitors identified in the deck; competition discussed only in abstract vs. incumbent modalities.
  • IP / defensibility: forward-looking statements mention IP enforcement capability; no patent specifics disclosed.

Team & funding ask / use of funds

  • Team: 500 people total; 300+ scientists/engineers on platform; industry-leading talent stated as a key asset.
  • Leadership named in deck: implied Tal Zaks (CMO, named in publication credit on slide 22); Giuseppe Ciaramella (also named in publication); no CEO/CFO slide.
  • Funding ask: Not explicitly stated (no "Use of Proceeds" slide; no round size or valuation disclosed).
  • Implied use of funds: sustain $300mm+ annual cash burn (2017E); scale manufacturing (Norwood GMP site); advance 12 DCs through clinic; build platform.
  • Existing investors / grants: DARPA, BARDA, Bill & Melinda Gates Foundation (non-dilutive). Equity investors not named.

Recommended financial model

  • Archetype + why: Pre-revenue biotech pipeline / cash-burn model with milestone revenue waterfall. Moderna has no product sales; revenue is entirely event-driven (partner milestones, grants). The correct archetype is a biotech pipeline cash-burn + milestone revenue model - not a standard 3-statement operating model. Model tracks: (a) milestone payments by program/partner triggered by clinical events, (b) cash runway vs. burn escalation, (c) optionality value of pipeline programs reaching NDA/commercialization in the 5–10 year window.
  • Forecast horizon & granularity: 2017–2027 (10 years); annual for milestones and burn; semi-annual or quarterly for cash runway to show when next capital raise is needed. 2017E budget is the anchor year.
  • Key drivers & assumptions:

*Revenue / Inflows:*

  • R&D reimbursement growth rate: $36mm (2016) → scale with partnership count; assume ~15–20% annual growth
  • Partnership milestone payments per program per stage (IND, Ph I, Ph II, NDA, approval): provides total upfronts by partner but no per-stage breakdown; assume clinical milestone tranches typical for mid-pharma deals ($10–50mm per Ph I readout)
  • New partnership probability and upfront size: 2–3 new partners per year at $50–200mm upfront
  • Grant income: ~$47mm/year average (2016: $225mm was exceptional/BARDA); normalize to $30–50mm/year

*Outflows / Burn:*

  • R&D spend: $225mm (2016E); 2017E >$300mm gross outflows stated; assume ~$275mm R&D component of that growing 20–25% annually as pipeline expands
  • G&A: $32mm (2016E); grow ~15% annually
  • CapEx: $39mm (2016E); ramp to ~$60–80mm by 2019 for Norwood GMP scale-up, then normalise
  • Net burn: ~($260mm) in 2016; 2017E >($300mm)

*Cash & Runway:*

  • Starting cash: $1,220mm (Q1 2017)
  • Runway at current burn: ~4 years without additional fundraising
  • Runway toggle: model equity raise triggers (e.g., when cash falls below $500mm floor)

*Pipeline progression (binary event schedule):*

  • mRNA-1440, mRNA-1851: Phase I ongoing (Dec 2015, May 2016) → Ph II readout assumed 2018–2019
  • mRNA-1325 (Zika): Ph I started Dec 2016 → readout 2018; DARPA/BARDA grant-funded
  • mRNA-1647 (CMV): IND filing 2017 → Ph I start 2017–2018
  • mRNA-4157 (PCV, Merck): IND filed → Ph I 2017–2018
  • mRNA AZD-8601 (VEGF-A, AZ): Ph I started Jan 2017 → readout 2018–2019
  • Assume 1 NDA filing in the 5-year window (most likely mRNA-1647 CMV or mRNA-1325 pandemic vaccine given urgency)
  • Scenarios (Base / Bull / Bear):
  • *Base:* 2 programs reach Ph II, 1 reaches NDA by 2027; burn grows 20%/year; 1 new equity raise ($500mm) in 2020; year-end cash never falls below $300mm.
  • *Bull:* 4 programs reach Ph II, 2 reach NDA; 2–3 additional major partnership deals ($200mm+ each); IPO 2018–2019 raises $600mm+.
  • *Bear:* 1–2 Phase I failures trigger partner pullback; burn continues; cash runway exhausted by 2021 without additional raise; no NDA before 2028.
  • Key flexed variables: program success rate, partnership upfront size, R&D burn rate, timing to NDA.
  • Required sheets / outputs:
  1. Assumptions - all drivers in one place, toggleable by scenario
  2. Pipeline tracker - 12 DCs by program, stage gate, milestone trigger, partner, milestone amount
  3. P&L / Burn statement - annual R&D, G&A, CapEx, net cash burn (mirrors slide 37 structure)
  4. Cash flow & runway - starting cash, inflows (milestones + grants + equity), outflows, year-end cash; runway in months
  5. Milestone waterfall - probability-weighted milestone revenue by program by year (expected value)
  6. Sensitivity table - burn rate × milestone timing; runway months as output
  7. Summary dashboard - year-end cash, active programs in clinic, cumulative milestones received, runway

Frequently asked

Is the Moderna financial model free?+

Yes. The Moderna model is a free Excel (.xlsx) download with live formulas. Sign up with your email and the workbook is yours to keep, review, and edit.

What's included in the model?+

A 5-year monthly forecast with P&L, cash flow and runway, valuation (exit multiple plus a DCF cross-check), MOIC/IRR returns, and unit economics, with live formulas throughout.

How was this model built?+

It was built from Moderna's pitch deck and publicly available information, then structured to investment-banking standards as a fully editable Excel model.

Can I change the assumptions?+

Yes. You can change assumptions and the live formulas will recalculate in the downloadable Excel model.

Have more financial modelling questions? Contact us

Alex Tapio, ex-Deloitte financial modelling expert

Created by ex-finance professionals

Hey, I’m Alex and I created Finamodel.

Over my years in the finance industry I kept building the same models over and over again. Same structure, same assumptions, different logo. So I started building frameworks to turn them into clean, reusable templates.

Every model here is one I’d actually use for a client, and I personally vet each one before it goes up.

I’m not an expert in every industry, but I’ve built enough models to know what belongs in one. And when something is completely foreign to me, I reach out to my network for experts to work on our models with us.

Having a template library on hand cuts a first build from hours to minutes.

Other Biotech/Pharma Startup Financial Models

Browse another startup in the same category.

Go further

Build the financial model you need with Fina AI

Browse templates, examples, and downloadable Excel models for the analysis you are trying to build. If you can't find your model, ask Fina to build a model for your specific needs.

Excel financial model spreadsheet preview showing Customer Rollforward
Fina interactive chat interface preview
Career Principles

Learn Financial Modelling Skills with industry-leading Career Principles

Breaking into the finance industry? Explore courses in Excel, financial modeling, valuation, data analytics, and AI for business and finance.

Career Principles lesson on preparing a cash flow statement in Excel
Career Principles Financial Analyst Program
Career Principles Python for Data Analysis
Career Principles AI for Business and Finance course